HeartFlow Public Company (NYSE:HFLO)

HeartFlow is on a mission to revolutionize precision heart care, with its non-invasive HeartFlow FFRCT Analysis leveraging AI to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. As such, the HeartFlow FFRct Analysis is well positioned to become an integral part of the standard of care for patients who are at risk for coronary artery disease (CAD) because of its potential to improve both clinical outcomes and the patient experience while reducing the cost of care.